SOURCE: Pipex Pharmaceuticals, Inc.

March 12, 2007 08:33 ET

Pipex Pharmaceuticals, Inc. to Present on March 13th at BioSquare 2007 Conference

ANN ARBOR, MI -- (MARKET WIRE) -- March 12, 2007 -- Pipex Pharmaceuticals, Inc. (OTCBB: PPXP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that Pipex is scheduled to make a presentation at BioSquare 2007, a premier European pharmaceutical partnering conference, to be held in Lyon, France during the week of March 12-14.

The Presentation details are as follows:
Event: BioSquare 2007
Presenter: Steve H. Kanzer, Chairman & Chief Executive Officer
When: Tuesday, March 13, 2007 at 5:45 p.m. (local time)
"With a robust late-stage product pipeline of oral drug candidates addressing major neurologic and fibrotic disease markets, Pipex is looking forward to introducing the company and its products to potential pharmaceutical partners at this major international corporate partnering venue," said Steve H. Kanzer, Pipex's Chairman & Chief Executive Officer.

Although live webcasting is not technically possible at this event in Lyon, France, Pipex expects to make a recorded version of the audio visual presentation available to shareholders following the event via Pipex's website at

About Pipex Pharmaceuticals, Inc.

Pipex Pharmaceuticals, Inc. (Pipex) is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of neurologic and fibrotic diseases. Pipex's strategy is to exclusively in-license proprietary, clinical-stage drug candidates and complete the further clinical testing, manufacturing and regulatory requirements sufficient to seek marketing authorizations via the filing of New Drug Applications (NDAs) with the FDA in the U.S. and Marketing Application Authorizations (MAAs) with the European Medicines Evaluation Agency (EMEA). For further information, please visit,

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect Pipex Pharmaceuticals, Inc. ("we" or "our") current expectations about its future results, performance, prospects and opportunities such as the formation of a strategic partnership or alliance for any of our products with a pharmaceutical or biotechnology company. Where possible, the Company has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. We cannot assure you that we will be able to successfully develop or commercialize products based on our technologies, particularly in light of the significant uncertainty inherent in developing, manufacturing and conducting preclinical and clinical trials of new pharmaceuticals, and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our cash expenditures will not exceed projected levels, that we will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that we will be able to successfully obtain any further grants and awards, maintain our existing grants which are subject to performance, that we will be able to patent, register or protect our technology from challenge and products from competition or maintain or expand our license agreements with our current licensors, that we will be able to enter into any partnership opportunities, strategic alliances or marketing transactions, or that our business strategy will be successful. All forward-looking statements made in this press release are made as of the date hereof, and the Company assumes no obligation to update the forward-looking statements included in this news release whether as a result of new information, future events, or otherwise. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements.

Contact Information

  • For Further Information Contact:

    Steve H. Kanzer, CPA, Esq.
    Chairman and Chief Executive Officer
    (734) 332-7800

    Charles Bisgaier, Ph.D.
    (734) 332-7800